Overview

Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine

Status:
Withdrawn
Trial end date:
2018-09-13
Target enrollment:
Participant gender:
Summary
Crossover, randomized, double blind: Q12h dosing in both periods; matching placebo for evening dosing during XR treatment; target dose: 100mg
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota
University of Minnesota - Clinical and Translational Science Institute
Collaborator:
Supernus Pharmaceuticals, Inc.
Treatments:
Topiramate